LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19.

    Padilla, Sergio / Telenti, Guillermo / Guillén, Lucía / García, José A / García-Abellán, Javier / Ding, Carolina / Mora, Antonia / García-Pachón, Eduardo / Gutiérrez, Félix / Masiá, Mar

    International journal of antimicrobial agents

    2020  Volume 56, Issue 4, Page(s) 106142

    Abstract: ... its predicting factors in subjects treated with combinations containing hydroxychloroquine (HCQ) for COVID-19 ... prolongation were observed during pharmacological therapy containing HCQ for COVID-19. Evidence of myocardial ... in women. Patients were treated under strict cardiac supervision. A total of 105 adults were included [56 ...

    Abstract This longitudinal, prospective cohort study aimed to assess risk of QTc interval prolongation and its predicting factors in subjects treated with combinations containing hydroxychloroquine (HCQ) for COVID-19. Moderate-to-severe QTc prolongation during therapy was defined as a QTc interval >470 ms in men or >480 ms in women. Patients were treated under strict cardiac supervision. A total of 105 adults were included [56% male; median (IQR) age 69 (57-79) years]. All patients received therapy with HCQ in combination with azithromycin (AZM), and 95 (90%) also with lopinavir/ritonavir (LPV/r). Concomitant medications classified as having risk of developing torsades de pointes (TdP) were simultaneously used in 81 patients (77%). Moderate-to-severe QTc prolongation was observed in 14 patients (13%), mostly at Days 3-5 from baseline, with 6 (6%) developing severe prolongation (>500 ms). There was no evidence of TdP arrhythmia or TdP-associated death. Adding LPV/r to HCQ+AZM did not significantly prolong the QTc interval. Multivariable Cox regression revealed that comedications with known risk of TdP (HR = 11.28, 95% CI 1.08-117.41), higher neutrophil-to-lymphocyte (NLR) ratio (HR = 1.10, 95% CI 1.03-1.18 per unit increase) and higher serum hs-cardiac troponin I (HR = 4.09, 95% CI 1.36-12.2 per unit increase) were major contributors to moderate-to-severe QTc prolongation. In this closely screened and monitored cohort, no complications derived from QTc prolongation were observed during pharmacological therapy containing HCQ for COVID-19. Evidence of myocardial injury with elevated troponin and strong inflammatory response, specifically higher NLR, are conditions requiring careful QTc interval monitoring.
    MeSH term(s) Aged ; Anti-Infective Agents/administration & dosage ; Anti-Infective Agents/adverse effects ; Azithromycin/administration & dosage ; Azithromycin/adverse effects ; Betacoronavirus/drug effects ; Betacoronavirus/immunology ; Betacoronavirus/pathogenicity ; Biomarkers/blood ; COVID-19 ; Coronavirus Infections/diagnosis ; Coronavirus Infections/drug therapy ; Coronavirus Infections/physiopathology ; Coronavirus Infections/virology ; Disease Progression ; Drug Combinations ; Female ; Humans ; Hydroxychloroquine/administration & dosage ; Hydroxychloroquine/adverse effects ; Intensive Care Units ; Long QT Syndrome/chemically induced ; Long QT Syndrome/diagnosis ; Long QT Syndrome/physiopathology ; Lopinavir/administration & dosage ; Lopinavir/adverse effects ; Lymphocytes/pathology ; Lymphocytes/virology ; Male ; Middle Aged ; Neutrophils/pathology ; Neutrophils/virology ; Pandemics ; Pneumonia, Viral/diagnosis ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/physiopathology ; Pneumonia, Viral/virology ; Prognosis ; Proportional Hazards Models ; Retrospective Studies ; Ritonavir/administration & dosage ; Ritonavir/adverse effects ; SARS-CoV-2 ; Treatment Outcome ; Troponin I/blood
    Chemical Substances Anti-Infective Agents ; Biomarkers ; Drug Combinations ; Troponin I ; lopinavir-ritonavir drug combination ; Lopinavir (2494G1JF75) ; Hydroxychloroquine (4QWG6N8QKH) ; Azithromycin (83905-01-5) ; Ritonavir (O3J8G9O825)
    Keywords covid19
    Language English
    Publishing date 2020-08-24
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 1093977-5
    ISSN 1872-7913 ; 0924-8579
    ISSN (online) 1872-7913
    ISSN 0924-8579
    DOI 10.1016/j.ijantimicag.2020.106142
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19

    Padilla, Sergio / Telenti, Guillermo / Guillén, Lucía / García, José A. / García-Abellán, Javier / Ding, Carolina / Mora, Antonia / García-Pachón, Eduardo / Gutiérrez, Félix / Masiá, Mar

    International Journal of Antimicrobial Agents

    2020  Volume 56, Issue 4, Page(s) 106142

    Keywords Microbiology (medical) ; Pharmacology (medical) ; Infectious Diseases ; General Medicine ; covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    ZDB-ID 1093977-5
    ISSN 1872-7913 ; 0924-8579
    ISSN (online) 1872-7913
    ISSN 0924-8579
    DOI 10.1016/j.ijantimicag.2020.106142
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  3. Article: Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19

    Padilla, Sergio / Telenti, Guillermo / Guillén, Lucía / García, José A / García-Abellán, Javier / Ding, Carolina / Mora, Antonia / García-Pachón, Eduardo / Gutiérrez, Félix / Masiá, Mar

    Int J Antimicrob Agents

    Abstract: ... its predicting factors in subjects treated with combinations containing hydroxychloroquine (HCQ) for COVID-19 ... prolongation were observed during pharmacological therapy containing HCQ for COVID-19. Evidence of myocardial ... in women. Patients were treated under strict cardiac supervision. A total of 105 adults were included [56 ...

    Abstract This longitudinal, prospective cohort study aimed to assess risk of QTc interval prolongation and its predicting factors in subjects treated with combinations containing hydroxychloroquine (HCQ) for COVID-19. Moderate-to-severe QTc prolongation during therapy was defined as a QTc interval >470 ms in men or >480 ms in women. Patients were treated under strict cardiac supervision. A total of 105 adults were included [56% male; median (IQR) age 69 (57-79) years]. All patients received therapy with HCQ in combination with azithromycin (AZM), and 95 (90%) also with lopinavir/ritonavir (LPV/r). Concomitant medications classified as having risk of developing torsades de pointes (TdP) were simultaneously used in 81 patients (77%). Moderate-to-severe QTc prolongation was observed in 14 patients (13%), mostly at Days 3-5 from baseline, with 6 (6%) developing severe prolongation (>500 ms). There was no evidence of TdP arrhythmia or TdP-associated death. Adding LPV/r to HCQ+AZM did not significantly prolong the QTc interval. Multivariable Cox regression revealed that comedications with known risk of TdP (HR = 11.28, 95% CI 1.08-117.41), higher neutrophil-to-lymphocyte (NLR) ratio (HR = 1.10, 95% CI 1.03-1.18 per unit increase) and higher serum hs-cardiac troponin I (HR = 4.09, 95% CI 1.36-12.2 per unit increase) were major contributors to moderate-to-severe QTc prolongation. In this closely screened and monitored cohort, no complications derived from QTc prolongation were observed during pharmacological therapy containing HCQ for COVID-19. Evidence of myocardial injury with elevated troponin and strong inflammatory response, specifically higher NLR, are conditions requiring careful QTc interval monitoring.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #726536
    Database COVID19

    Kategorien

  4. Article: Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19

    Padilla, Sergio / Telenti, Guillermo / Guillén, Lucía / García, José A / García-Abellán, Javier / Ding, Carolina / Mora, Antonia / García-Pachón, Eduardo / Gutiérrez, Félix / Masiá, Mar

    International journal of antimicrobial agents. 2020 Oct., v. 56, no. 4

    2020  

    Abstract: ... its predicting factors in subjects treated with combinations containing hydroxychloroquine (HCQ) for COVID-19 ... prolongation were observed during pharmacological therapy containing HCQ for COVID-19. Evidence of myocardial ... in women. Patients were treated under strict cardiac supervision. A total of 105 adults were included [56 ...

    Institution COVID19-Elx Group
    Abstract This longitudinal, prospective cohort study aimed to assess risk of QTc interval prolongation and its predicting factors in subjects treated with combinations containing hydroxychloroquine (HCQ) for COVID-19. Moderate-to-severe QTc prolongation during therapy was defined as a QTc interval >470 ms in men or >480 ms in women. Patients were treated under strict cardiac supervision. A total of 105 adults were included [56% male; median (IQR) age 69 (57–79) years]. All patients received therapy with HCQ in combination with azithromycin (AZM), and 95 (90%) also with lopinavir/ritonavir (LPV/r). Concomitant medications classified as having risk of developing torsades de pointes (TdP) were simultaneously used in 81 patients (77%). Moderate-to-severe QTc prolongation was observed in 14 patients (13%), mostly at Days 3–5 from baseline, with 6 (6%) developing severe prolongation (>500 ms). There was no evidence of TdP arrhythmia or TdP-associated death. Adding LPV/r to HCQ+AZM did not significantly prolong the QTc interval. Multivariable Cox regression revealed that comedications with known risk of TdP (HR = 11.28, 95% CI 1.08–117.41), higher neutrophil-to-lymphocyte (NLR) ratio (HR = 1.10, 95% CI 1.03–1.18 per unit increase) and higher serum hs-cardiac troponin I (HR = 4.09, 95% CI 1.36–12.2 per unit increase) were major contributors to moderate-to-severe QTc prolongation. In this closely screened and monitored cohort, no complications derived from QTc prolongation were observed during pharmacological therapy containing HCQ for COVID-19. Evidence of myocardial injury with elevated troponin and strong inflammatory response, specifically higher NLR, are conditions requiring careful QTc interval monitoring.
    Keywords Coronavirus infections ; adults ; age ; arrhythmia ; azithromycin ; blood serum ; cohort studies ; death ; inflammation ; males ; men ; monitoring ; patients ; prediction ; regression analysis ; risk ; therapeutics ; troponin I ; women
    Language English
    Dates of publication 2020-10
    Publishing place Elsevier Ltd
    Document type Article
    Note NAL-light
    ZDB-ID 1093977-5
    ISSN 1872-7913 ; 0924-8579
    ISSN (online) 1872-7913
    ISSN 0924-8579
    DOI 10.1016/j.ijantimicag.2020.106142
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

To top